[Canakinumab, a monoclonal antibody against IL-1β, with potential utility in different inflammatory processes].
Canakinumab is a fully human monoclonal antibody targeted at IL-1β which has shown to be effective in the control the symptoms of patients affected by CAPS and other autoinflammatory diseases. Its effect is rapid and sustained. In clinical trials conducted up until now, the most common adverse effects reported with the use of this drug have been different types of infections, migraines and vertigo.